Supply Chain Intelligence

ACADIA Pharmaceuticals Inc. Supply Chain

ACAD supply chain intelligence for ACADIA Pharmaceuticals Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ACAD ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
14Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

ACADIA Pharmaceuticals Inc. (ACAD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships
1Distinct source URLs
6High confidence
0.710Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

ACADIA Pharmaceuticals Inc. Suppliers

TickerNameConfidenceEvidence
NEUREN NEUREN 90% The Company paid Neuren an upfront license fee of $ 10.0 million and it may be required to pay up to an additional $ 455.0 million in milestone payments based on the achievement of certain developmen…
SANIONA-A-S SANIONA-A-S 90% The Company paid Saniona an upfront fee of $ 28.0 million and it may be required to pay up to $ 582.0 million in milestone payments based on the achievement of certain development and annual net sale…
STOKE-THERAPEUTICS-INC STOKE-THERAPEUTICS-INC 90% The Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first quarter of 2022 as there is no altern…
GHRS GH Research PLC 72% Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated…
STOK Stoke Therapeutics, Inc. 72% Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK g…
MPLT MapLight Therapeutics, Inc. 62% Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require u…

ACADIA Pharmaceuticals Inc. Customers

TickerNameConfidenceEvidence
STOK Stoke Therapeutics, Inc. 72% Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the …
STOK Stoke Therapeutics, Inc. 72% 2023 as there is no alternative use for the asset. In January 2022, the Company entered into a license and collaboration agreement with Stoke Therapeutics, Inc. (Stoke) to discover, develop and comme…
ACADIA-GMBH ACADIA-GMBH 62% inst any product liability claims that may be brought against us related to our products or our product candidates; and • general and industry-specific economic conditions. We believe that comparison…
ACADIA-PHARMACEUTICALS-GMBH ACADIA-PHARMACEUTICALS-GMBH 62% inst any product liability claims that may be brought against us related to our products or our product candidates; and • general and industry-specific economic conditions. We believe that comparison…
AUPH Aurinia Pharmaceuticals Inc. 62% Reciprocal relationship from AUPH graph: Reciprocal relationship from ACAD graph: . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for a…
AUROBINDO-PHARMA-LIMITED AUROBINDO-PHARMA-LIMITED 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…
AUROBINDO-PHARMA-USA-INC AUROBINDO-PHARMA-USA-INC 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…
HETERO-LABS-LIMITED HETERO-LABS-LIMITED 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…
HETERO-USA-INC HETERO-USA-INC 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…
MSN-LABORATORIES-PRIVATE-LTD MSN-LABORATORIES-PRIVATE-LTD 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…
NEUREN-PHARMACEUTICALS-LIMITED NEUREN-PHARMACEUTICALS-LIMITED 62% including third-party manufacturing costs, freight, and indirect overhead costs. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on managemen…
TEVA Teva Pharmaceutical Industries Limited 62% Reciprocal relationship from TEVA graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from ACAD graph: . Under the terms of the agreement,…
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD TEVA-PHARMACEUTICAL-INDUSTRIES-LTD 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…
TEVA-PHARMACEUTICALS-USA-INC TEVA-PHARMACEUTICALS-USA-INC 62% . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q…

ACADIA Pharmaceuticals Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ACAD-DEBT Debt stack $22,000 90% Market cache reports total debt of $22,000.
ACAD-DEBT-7450 Warrants outstanding: 0.35 90% xbrl warrant detail from xbrl 2012-12-31.

ACADIA Pharmaceuticals Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for ACADIA Pharmaceuticals Inc..

ACADIA Pharmaceuticals Inc. Ownership

HolderNameConfidenceEvidence
ACAD-OWNER-BAKER-BROS-ADVISORS-LP BAKER BROS. ADVISORS LP 90% 13F overlay lists BAKER BROS. ADVISORS LP as top holder; 346 tracked holders.

ACADIA Pharmaceuticals Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ZLDPF Zealand Pharma A/S 100.00 2
ADCT ADC Therapeutics SA 100.00 2
GNMSF Genmab A/S 100.00 2
MYGN Myriad Genetics, Inc. 100.00 2
MPLT MapLight Therapeutics, Inc. 100.00 1 ['supplier']
TEVA Teva Pharmaceutical Industries Limited 100.00 1 ['customer']
AUPH Aurinia Pharmaceuticals Inc. 100.00 1 ['customer']
BMY Bristol-Myers Squibb Company 50.00 2
SVRE SaverOne 2014 Ltd. 50.00 2
ARDX Ardelyx, Inc. 50.00 2
BMYMP Bristol-Myers Squibb Co 50.00 2
TXMD TherapeuticsMD, Inc. 50.00 2
MCK McKesson Corporation 50.00 2
KR The Kroger Co. 50.00 2
NBIX Neurocrine Biosciences, Inc. 50.00 2
KZR Kezar Life Sciences, Inc. 50.00 2
NMRA Neumora Therapeutics, Inc. 50.00 2
NONOF Novo Nordisk A/S 50.00 2
MS-PE Morgan Stanley 50.00 2
SGMT Sagimet Biosciences Inc. 50.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for ACADIA Pharmaceuticals Inc..

Unlock full ACAD data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
ACAD
Unlock ACAD Supply Chain Data
Verified relationships include:
NEURENNEURENSupplier90%
SANIONA-A-SSANIONA-A-SSupplier90%
STOKStoke Therapeutics, Inc.Customer72%
STOKStoke Therapeutics, Inc.Customer72%
+19 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →